The NF-κB specific inhibitor DHMEQ prevents thrombus formation in a mouse model of antiphospholipid syndrome
Background: β2-glycoprotein I (β2GPI)-dependent antiphospholipid antibodies (aPLs) are considered to play a pivotal pathogenic role in antiphospholipid syndrome (APS) by inducing the expression of tissue factor, inflammatory cytokines, and chemokines, most of which are dependent upon the NF-κB pathw...
Main Authors: | Misato Nishimura, Tokiko Nii, Gulzhan Trimova, Shuhei Miura, Kazuo Umezawa, Akira Ushiyama, Tetsuo Kubota |
---|---|
Format: | Article |
Language: | English |
Published: |
Society of Diabetic Nephropathy Prevention
2013-04-01
|
Series: | Journal of Nephropathology |
Subjects: | |
Online Access: | https://nephropathol.com/PDF/jnp-2-114.pdf |
Similar Items
-
Importance of Novel Intraperitoneal Therapy of NF-kappa B Inhibitor DHMEQ
by: Sh. Kh. Gantsev, et al.
Published: (2019-04-01) -
Inhibition of Cellular and Animal Inflammatory Disease Models by NF-κB Inhibitor DHMEQ
by: Jun Ma, et al.
Published: (2021-09-01) -
Intracardiac thrombus in a patient with catastrophic antiphospholipid syndrome: an autopsy case report and review of the literature
by: Waisayarat J, et al.
Published: (2019-08-01) -
Antitumour Activity of Dehydroxymethylepoxyquinomycin (DHMEQ): a Literature Review
by: K. Umezawa, et al.
Published: (2021-04-01) -
Antiphospholipid syndrome and cancer
by: Razvan Adrian Ionescu
Published: (2021-03-01)